Cheryl Guttman Krader
Laser-activated PCa therapy promising in phase III study
Researchers evaluate an experimental treatment called vascular-targeted photodynamic therapy in men with localized prostate cancer.
Bone metastases Tx: 12-week dosing interval appears feasible
Results of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.
Studies reveal drop in PCa treatment, rise in metastatic disease
Findings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.
Delay from biopsy to RP: Who is at risk of recurrence?
The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.
Device efficacious for treating IC with Hunner’s lesions
A novel lidocaine-releasing intravesical system (LiRIS, Allergan) demonstrated promising efficacy and safety in a small proof-of-concept study investigating its use as a treatment for women suffering from interstitial cystitis with Hunner’s lesions, reported Kenneth M. Peters, MD, at the AUA annual meeting in San Diego.
PD-L1 inhibitor shows promise as first-line therapy
PD-L1 inhibitor shows promise as first-line therapy
A recently approved treatment for urothelial carcinoma provides durable responses when used as first-line treatment in patients who are ineligible for cisplatin-based therapy, according to a recent study.
Female SUI system shows durable efficacy, safety
After meeting its primary endpoint at 3 months in a prospective, randomized, sham-controlled clinical trial, an intravesical pressure-attenuation balloon (Vesair Bladder Control System, Solace Therapeutics) for treatment of female stress urinary incontinence demonstrated durable efficacy and safety after 12 months of follow-up.
QoL prognostic in mCRPC patients on salvage therapy
Clinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Negative mpMRI does not rule out significant PCa
As interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.
Prostate Ca: Novel model predicts ‘true cancer state’
Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.